From: Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
 | Primary treatment with HSRT alone | Primary treatment with WBRT + HSRT | Salvage treatment with HSRT |
---|---|---|---|
Total number | 19 | 10 | 11 |
Gender | Â | Â | Â |
   Male | 13 | 6 | 5 |
   Female | 6 | 4 | 6 |
Median Age, y (range) | 55 (38-87) | 56 (40-76) | 47 (35-73) |
   ≥ 65 | 6 | 4 | 1 |
   < 65 | 13 | 6 | 10 |
No. of brain metastases | Â | Â | Â |
   1 | 10 | 4 | 5 |
   2 | 9 | 3 | 2 |
   3 | 0 | 2 | 4 |
   4 | 0 | 1 | 0 |
Primary tumor | Â | Â | Â |
   Non-small-cell lung cancer | 10 | 6 | 4 |
   Small-cell lung cancer | 2 | 2 | 6 |
   Breast cancer | 1 | 2 | 0 |
   Other | 6 | 0 | 1 |
Control of primary tumor | Â | Â | Â |
   Controlled | 16 | 6 | 9 |
   Uncontrolled | 3 | 4 | 2 |
Extracranial metastasis | Â | Â | Â |
   No | 7 | 2 | 8 |
   Yes | 12 | 8 | 3 |
Karnofsky Performance Score | Â | Â | Â |
   ≥ 80 | 10 | 3 | 7 |
   < 80 | 9 | 7 | 4 |
RPA class | Â | Â | Â |
   1 | 4 | 1 | 7 |
   2 | 12 | 8 | 4 |
   3 | 3 | 1 | 0 |
Hypofractionated stereotactic radiotherapy (HSRT) Boost | 13 | 1 | 9 |